TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04626791
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05354700
Drug: HLX07
Normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX07 is a recombinant humanized anti-EGFR monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
Study: NCT05354700
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX10 is a recombinant humanized anti-PD-1 monoclonal antibody injection, developed by Shanghai Henlius Biotech, Inc.
Study: NCT05354700
Drug: carboplatin and etoposide
Normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapeutics
Study: NCT05388903
Drug: DS-2325a
Normalized name: DS-2325a
DrugBank: DS-2325a (DB18134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (starting dose 30 mg)
Study: NCT05388903
Drug: DS-2325a
Normalized name: DS-2325a
DrugBank: DS-2325a (DB18134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (starting dose 100 mg)
Study: NCT02635841
Drug: Deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferriprox (deferiprone) 100 mg/mL oral solution
Study: NCT04647526
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)
Study: NCT04647526
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide (160 mg orally qd)
Study: NCT05043649
Drug: Camsirubicin
Normalized name: Camsirubicin
DrugBank: Camsirubicin (DB13103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose escalation of camsirubicin will start at 265 mg/m2, with dose increments of 50% until a Grade 2 non-hematologic toxicity is observed at which point subsequent dose escalations will be in increments of 25% until an MTD is identified in patients with ASTS.
Study: NCT05626829
Drug: Tranilast
Normalized name: Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast capsules 100mg 3 times per day when reradiation
Study: NCT05084872
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
Study: NCT00006154
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg tablets equaling 1600 mg daily
Study: NCT00006154
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg liquid capsules equaling 400 mg daily
Study: NCT00006154
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
Study: NCT00006154
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg capsules equaling 600 mg daily
Study: NCT00006154
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-40 mg capsules equaling 60 or 80 mg daily
Study: NCT00006154
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250-400 mg E.coated tablets equaling 250 or 400 mg daily
Study: NCT00006154
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection equaling 15 x 10\^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
Study: NCT04475744
Drug: G-CSF treatment for Bone marrow derived stem cell Mobilization
Normalized name: G-CSF (CHO cell derived)
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mobilization treatment. On the fifth day, collection will be started.
Study: NCT06534346
Drug: 15 mg DA-302168S tablet
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration.
Study: NCT06427785
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
Study: NCT04633057
Drug: TJ101
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
Study: NCT04146571
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, ALK inhibitor
Study: NCT05847244
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
Study: NCT05089344
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: growth hormone
Study: NCT05089344
Drug: Clomiphene citrate daily and recombinant FSH (Gonal-F®)
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate daily and recombinant FSH (Gonal-F®)
Study: NCT05450432
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will start treatment including two ketamine infusion visits per week during the acute phase, for up to eight ketamine infusion visits. Participants will then be transitioned to maintenance with intranasal esketamine.
Study: NCT01151592
Drug: Iron Sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
Study: NCT06102252
Drug: Paclitaxel/epirubcin/carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adjuvant treatment in endometrial carcinoma
Study: NCT06102252
Drug: Paclitaxel/carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose dense paclitaxel/carboplatin
Study: NCT04755712
Drug: Sodium Chloride Injection
Normalized name: Sodium Chloride Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2).
Study: NCT04755712
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine via pump (patient controlled analgesia)
Study: NCT05450432
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After one month from the eighth ketamine infusion visit, participants will initiate weekly esketamine for 12 weeks, for a total of 13 esketamine treatments. The esketamine visits will happen as per standard of care at the clinic and as instructed by the SPRAVATO Risk Evaluation and Mitigation Strategy.
Study: NCT06013995
Drug: BMS-986326
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04667234
Drug: AMG 510
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an oral tablet.
Study: NCT06098209
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
Study: NCT06098209
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive propofol 0.3-4 mg/kg/h.
Study: NCT05678192
Drug: oral menopausal hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
Study: NCT05678192
Drug: transdermal menopausal hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
Study: NCT05735951
Drug: STIRIPENTOL oral administration
Normalized name: stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration of:~* Days 1 and 2: 1000 mg of stiripentol (single dose at the end of breakfast),~* Day 3 to Day 14: 1000 mg of stiripentol bis in die (BID) (approximately 12 hours apart, at the end of breakfast and at the end of dinner),~* Day 15: 1000 mg of stiripentol (single dose at the end of breakfast).
Study: NCT05945901
Drug: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
Study: NCT05945901
Drug: HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
Study: NCT05051865
Drug: camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab combined with SHR1020 for advanced melanoma
Study: NCT04853524
Drug: JNJ-56136379
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 tablets will be administered orally.
Study: NCT04853524
Drug: Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
Normalized name: bictegravir / emtricitabine / tenofovir alafenamide
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A combination of BIC, FTC and TAF will be administered orally.
Study: NCT05802238
Drug: Tranexamic acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery
Study: NCT06227585
Drug: Bevonescein
Normalized name: Bevonescein
DrugBank: Bevonescein (DB19021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before surgery.
Study: NCT05256056
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efficacy of bupivacaine in different volumes
Study: NCT05085028
Drug: Pembrolizumab 25 MG/ML [Keytruda]
Normalized name: pembrolizumab 25 MG/ML [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
Study: NCT04767633
Drug: split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing
Normalized name: magnesium sulfate / potassium sulfate / sodium sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
Study: NCT05203276
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg，SC，Q3W，d1
Study: NCT05203276
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 210mg，CIV，Q3W，d1-3
Study: NCT03745664
Drug: Methylprednisolone Sodium Succinate
Normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
Study: NCT01297933
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
Study: NCT05603039
Drug: QL1706
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Study: NCT05603039
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Study: NCT06067412
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Efficacy in fits
Study: NCT06670274
Drug: HC002 SAD
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1 will enroll 40 participants across 5 cohorts.~Route of administration: Oral Dose interval and frequency: Single oral dose range across 5 cohorts.
Study: NCT06669975
Drug: AP402 (Part 1 Dose esclation)
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.
Study: NCT06669975
Drug: AP402 (Part 2 Dose Expansion)
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.
Study: NCT06670690
Drug: Atenolol 50 MG
Normalized name: atenolol 50 MG
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be premedicated with atenolol (50mg)
Study: NCT06670690
Drug: Propranolol Pill
Normalized name: propranolol Pill
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be premedicated with propranolol (10mg)
Study: NCT06670690
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will be premedicated with Ivabradine (5mg)
Study: NCT05667727
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive salbutamol as 4th nebulization.
Study: NCT06281886
Drug: Induction Immunotherapy-Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 240mg iv. drip, Q3W, 2 cycles
Study: NCT06281886
Drug: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.
Study: NCT06281886
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.
Study: NCT05501860
Drug: AG-920
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-920 Sterile Topical Ophthalmic Solution
Study: NCT06630871
Drug: Distitamab Vedotin in combination with Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day after the initial TURBt procedure, use trastuzumab (200mg)+ Distitamab Vedotin (120mg \[≤ 60Kg\] or 2.0mg/Kg \[\>60Kg\]) every 3 weeks (Q3W). Simultaneously arrange for the patient to complete a second TURBt within 6 weeks, and continue to use 3 courses of Trastuzumab+Vediximab (Q3W) after surgery until the endpoint of 3-year follow-up
Study: NCT00001009
Drug: Dextran sulfate
Normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05601973
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.
Study: NCT05601973
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.
Study: NCT05601973
Drug: Zirabev
Normalized name: Zirabev
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
Study: NCT05198752
Drug: Neoantigen mRNA Personalised Cancer SW1115C3
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT04852081
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
Study: NCT04852081
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
Study: NCT04852081
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
Study: NCT04852081
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
Study: NCT04852081
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
Study: NCT04852081
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
Study: NCT04852081
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
Study: NCT04852081
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
Study: NCT04852081
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
Study: NCT05378399
Drug: Descovy or Truvada
Normalized name: Descovy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Descovy or Truvada prescribed with digital pills for PrEP
Study: NCT05997238
Drug: without triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.